+ All Categories
Home > Documents > Therapeutic e ect of POL101 eyedrops, anti-VEGF agents, in vitro … · 2020. 8. 25. · HUVEC...

Therapeutic e ect of POL101 eyedrops, anti-VEGF agents, in vitro … · 2020. 8. 25. · HUVEC...

Date post: 01-Apr-2021
Category:
Upload: others
View: 1 times
Download: 0 times
Share this document with a friend
10
Posted on Authorea 25 Aug 2020 — The copyright holder is the author/funder. All rights reserved. No reuse without permission. — https://doi.org/10.22541/au.159833944.48218110 — This a preprint and has not been peer reviewed. Data may be preliminary. Therapeutic effect of POL101 eyedrops, anti-VEGF agents, in vitro and in vivo models DONGIN LEE 1 , Ji-Yeon Yu 1 , Yu-sun Kang 1 , Hee Kyung Park 2 , and Hye Joo Kim 1 1 Seasun Therapeutics Inc 2 SEASUN BIOMATERIALS, Inc August 25, 2020 Abstract Background and Purpose: Choroidal neovascularization (CNV) is the leading cause of blindness in patients with age-related macular degeneration (AMD). Several studies reported increased levels of vascular endothelial growth factor (VEGF) in retinal pigment epithelium (RPE) from AMD patients. The aim of this study was to investigate the efficacy of the VEGF-A targeted peptide nucleic acid (PNA) drug, POL101 eyedrops, in retinal pigment epithelial cell and laser-induced CNV animal model. Experimental Approach: POL101 is a PNA based-Antisense oligonucleotide (ASO) drug which chemically improved properties for stability and delivery to tissue through nano-grade particle size. To evaluate the efficacy of POL101, we performed to in vitro assay in retinal pigment cell and Fundus fluorescein angiography (FFA), optical coherence tomography (OCT) scanning, and electroretinography (ERG) in CNV-induced lesion. Key Results: First, the efficacy of POL101 was verified in ARPE-19 and HUVEC cells. And then, we confirmed that POL101 eyedrops was significantly decreased CNV area to 54.2% compared with vehicle in laser-induced CNV lesion and reduced VEGF level in choroid tissue without cellular apoptosis. Also, Photocoagulation demonstrated that the average CNV lesion area was reduced and recovered retina function in POL101 group. The mRNA expression of VEGF in mouse retina, intracellular adhesion molecule-1 (ICAM-1), matrix metallopeptidases -2 (MMP-2) and 9 (MMP-9) were significantly reduced in POL101 eyedrops-treated group. Conclusion and Implications: In conclusion, POL101 eyedrops was effectively suppressed VEGF-mediated CNV than aflibercept and has the potential to be effective without side effects and could replace biologics. Hosted file manuscript.pdf available at https://authorea.com/users/351318/articles/477442-therapeutic- effect-of-pol101-eyedrops-anti-vegf-agents-in-vitro-and-in-vivo-models 1
Transcript
Page 1: Therapeutic e ect of POL101 eyedrops, anti-VEGF agents, in vitro … · 2020. 8. 25. · HUVEC cells. And then, we con rmed that POL101 eyedrops was signi cantly decreased CNV area

Postedon

Authorea

25Aug2020

—Thecopyrigh

tholder

istheau

thor/funder.Allrights

reserved.Noreuse

withou

tpermission

.—

https://doi.org/10.22541/au

.159833944.48218110—

This

apreprintan

dhasnotbeenpeerreviewed.Data

may

bepreliminary.

Therapeutic effect of POL101 eyedrops, anti-VEGF agents, in vitro

and in vivo models

DONGIN LEE1, Ji-Yeon Yu1, Yu-sun Kang1, Hee Kyung Park2, and Hye Joo Kim1

1Seasun Therapeutics Inc2SEASUN BIOMATERIALS, Inc

August 25, 2020

Abstract

Background and Purpose: Choroidal neovascularization (CNV) is the leading cause of blindness in patients with age-related

macular degeneration (AMD). Several studies reported increased levels of vascular endothelial growth factor (VEGF) in retinal

pigment epithelium (RPE) from AMD patients. The aim of this study was to investigate the efficacy of the VEGF-A targeted

peptide nucleic acid (PNA) drug, POL101 eyedrops, in retinal pigment epithelial cell and laser-induced CNV animal model.

Experimental Approach: POL101 is a PNA based-Antisense oligonucleotide (ASO) drug which chemically improved properties

for stability and delivery to tissue through nano-grade particle size. To evaluate the efficacy of POL101, we performed to in

vitro assay in retinal pigment cell and Fundus fluorescein angiography (FFA), optical coherence tomography (OCT) scanning,

and electroretinography (ERG) in CNV-induced lesion. Key Results: First, the efficacy of POL101 was verified in ARPE-19 and

HUVEC cells. And then, we confirmed that POL101 eyedrops was significantly decreased CNV area to 54.2% compared with

vehicle in laser-induced CNV lesion and reduced VEGF level in choroid tissue without cellular apoptosis. Also, Photocoagulation

demonstrated that the average CNV lesion area was reduced and recovered retina function in POL101 group. The mRNA

expression of VEGF in mouse retina, intracellular adhesion molecule-1 (ICAM-1), matrix metallopeptidases -2 (MMP-2) and 9

(MMP-9) were significantly reduced in POL101 eyedrops-treated group. Conclusion and Implications: In conclusion, POL101

eyedrops was effectively suppressed VEGF-mediated CNV than aflibercept and has the potential to be effective without side

effects and could replace biologics.

Hosted file

manuscript.pdf available at https://authorea.com/users/351318/articles/477442-therapeutic-

effect-of-pol101-eyedrops-anti-vegf-agents-in-vitro-and-in-vivo-models

1

Page 2: Therapeutic e ect of POL101 eyedrops, anti-VEGF agents, in vitro … · 2020. 8. 25. · HUVEC cells. And then, we con rmed that POL101 eyedrops was signi cantly decreased CNV area

Postedon

Authorea

25Aug2020

—Thecopyrigh

tholder

istheau

thor/funder.Allrights

reserved.Noreuse

withou

tpermission

.—

https://doi.org/10.22541/au

.159833944.48218110—

This

apreprintan

dhasnotbeenpeerreviewed.Data

may

bepreliminary.

2

Page 3: Therapeutic e ect of POL101 eyedrops, anti-VEGF agents, in vitro … · 2020. 8. 25. · HUVEC cells. And then, we con rmed that POL101 eyedrops was signi cantly decreased CNV area

Postedon

Authorea

25Aug2020

—Thecopyrigh

tholder

istheau

thor/funder.Allrights

reserved.Noreuse

withou

tpermission

.—

https://doi.org/10.22541/au

.159833944.48218110—

This

apreprintan

dhasnotbeenpeerreviewed.Data

may

bepreliminary.

3

Page 4: Therapeutic e ect of POL101 eyedrops, anti-VEGF agents, in vitro … · 2020. 8. 25. · HUVEC cells. And then, we con rmed that POL101 eyedrops was signi cantly decreased CNV area

Postedon

Authorea

25Aug2020

—Thecopyrigh

tholder

istheau

thor/funder.Allrights

reserved.Noreuse

withou

tpermission

.—

https://doi.org/10.22541/au

.159833944.48218110—

This

apreprintan

dhasnotbeenpeerreviewed.Data

may

bepreliminary.

4

Page 5: Therapeutic e ect of POL101 eyedrops, anti-VEGF agents, in vitro … · 2020. 8. 25. · HUVEC cells. And then, we con rmed that POL101 eyedrops was signi cantly decreased CNV area

Postedon

Authorea

25Aug2020

—Thecopyrigh

tholder

istheau

thor/funder.Allrights

reserved.Noreuse

withou

tpermission

.—

https://doi.org/10.22541/au

.159833944.48218110—

This

apreprintan

dhasnotbeenpeerreviewed.Data

may

bepreliminary.

5

Page 6: Therapeutic e ect of POL101 eyedrops, anti-VEGF agents, in vitro … · 2020. 8. 25. · HUVEC cells. And then, we con rmed that POL101 eyedrops was signi cantly decreased CNV area

Postedon

Authorea

25Aug2020

—Thecopyrigh

tholder

istheau

thor/funder.Allrights

reserved.Noreuse

withou

tpermission

.—

https://doi.org/10.22541/au

.159833944.48218110—

This

apreprintan

dhasnotbeenpeerreviewed.Data

may

bepreliminary.

6

Page 7: Therapeutic e ect of POL101 eyedrops, anti-VEGF agents, in vitro … · 2020. 8. 25. · HUVEC cells. And then, we con rmed that POL101 eyedrops was signi cantly decreased CNV area

Postedon

Authorea

25Aug2020

—Thecopyrigh

tholder

istheau

thor/funder.Allrights

reserved.Noreuse

withou

tpermission

.—

https://doi.org/10.22541/au

.159833944.48218110—

This

apreprintan

dhasnotbeenpeerreviewed.Data

may

bepreliminary.

7

Page 8: Therapeutic e ect of POL101 eyedrops, anti-VEGF agents, in vitro … · 2020. 8. 25. · HUVEC cells. And then, we con rmed that POL101 eyedrops was signi cantly decreased CNV area

Postedon

Authorea

25Aug2020

—Thecopyrigh

tholder

istheau

thor/funder.Allrights

reserved.Noreuse

withou

tpermission

.—

https://doi.org/10.22541/au

.159833944.48218110—

This

apreprintan

dhasnotbeenpeerreviewed.Data

may

bepreliminary.

8

Page 9: Therapeutic e ect of POL101 eyedrops, anti-VEGF agents, in vitro … · 2020. 8. 25. · HUVEC cells. And then, we con rmed that POL101 eyedrops was signi cantly decreased CNV area

Postedon

Authorea

25Aug2020

—Thecopyrigh

tholder

istheau

thor/funder.Allrights

reserved.Noreuse

withou

tpermission

.—

https://doi.org/10.22541/au

.159833944.48218110—

This

apreprintan

dhasnotbeenpeerreviewed.Data

may

bepreliminary.

9

Page 10: Therapeutic e ect of POL101 eyedrops, anti-VEGF agents, in vitro … · 2020. 8. 25. · HUVEC cells. And then, we con rmed that POL101 eyedrops was signi cantly decreased CNV area

Postedon

Authorea

25Aug2020

—Thecopyrigh

tholder

istheau

thor/funder.Allrights

reserved.Noreuse

withou

tpermission

.—

https://doi.org/10.22541/au

.159833944.48218110—

This

apreprintan

dhasnotbeenpeerreviewed.Data

may

bepreliminary.

10


Recommended